Search hospitals

>

Maine

>

Bangor

Eastern Maine Medical Center

Claim this profile

Bangor, Maine 04401

Global Leader in Breast Cancer

Global Leader in Cancer

Conducts research for Brain Tumor

Conducts research for Lung Cancer

Conducts research for Leukemia

356 reported clinical trials

11 medical researchers

Photo of Eastern Maine Medical Center in BangorPhoto of Eastern Maine Medical Center in BangorPhoto of Eastern Maine Medical Center in Bangor

Summary

Eastern Maine Medical Center is a medical facility located in Bangor, Maine. This center is recognized for care of Breast Cancer, Cancer, Brain Tumor, Lung Cancer, Leukemia and other specialties. Eastern Maine Medical Center is involved with conducting 356 clinical trials across 586 conditions. There are 11 research doctors associated with this hospital, such as Sarah J. Sinclair, Nadine P. SantaCruz, Daniel L. Callaway, and Clifford Singer.

Area of expertise

1

Breast Cancer

Global Leader

Eastern Maine Medical Center has run 49 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
Stage IV
ER positive
2

Cancer

Global Leader

Eastern Maine Medical Center has run 40 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II

Top PIs

Clinical Trials running at Eastern Maine Medical Center

Lung Cancer

Testicular cancer

Neuroblastoma

Brain Tumor

Ovarian Carcinoma

Ovarian Tumors

Testicular Carcinoma

Ovarian Choriocarcinoma

Cancer

Breast Cancer

Image of trial facility.

Thoracotomy vs Thoracoscopy

for Metastatic Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.

Recruiting

2 awards

Phase 3

7 criteria

Image of trial facility.

Treatment Timing

for Non-Small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Eastern Maine Medical Center?

Where is Eastern Maine Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Eastern Maine Medical Center accept?

What awards or recognition has Eastern Maine Medical Center received?